You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1306-ESGO Effect of the COVID-19 pandemic on primary therapy and oncologic outcomes in women with advanced stage tubo-ovarian carcinoma in a tertiary cancer center

Article Text

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1306-ESGO Effect of the COVID-19 pandemic on primary therapy and oncologic outcomes in women with advanced stage tubo-ovarian carcinoma in a tertiary cancer center
Free
  1. Ane Gerda Z Eriksson1,
  2. Ragni K Idland1,
  3. Larissa Elisabeth Hoffmann2,
  4. Torbjørn Paulsen2,
  5. Yun Wang2,
  6. Tone Skeie Jensen2,
  7. Brynhildur Eyjolfsdottir Eyjolfsdottir2,
  8. Olesya Solheim2,
  9. Pernille Bjerre Trent2,
  10. Ben Davidson3,
  11. Anne Dørum2 and
  12. Milada Cvancarova Småstuen4
  1. 1Department of Gynecologic Oncology, The Norwegian Radiumhospital, Oslo University Hospital, Oslo, Norway
  2. 2Department of Gynecologic Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  3. 3Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  4. 4Department of Nursing and Health Promotion, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway

Abstract

Introduction/Background The COVID-19 pandemic resulted in significant alterations in access to health care services globally. The Norwegian Radium Hospital was declared ‘Covid-free’ to maintain cancer care at the same level as prior to the pandemic. Despite this, concerns regarding possible delayed diagnosis and suboptimal therapy have been raised.Objective: To explore if management and outcomes for women with advanced stage high-grade serous tubo-ovarian carcinoma (HGSC) was altered during the COVID-19 pandemic.

Methodology Women with stage III/IV HGSC from 2017–2021 were identified in our institutional database. Pre-Covid cohort January 2017 – March 2020, and Covid-cohort April 2020 – August 2021. Demographics, treatment characteristics and oncologic outcomes were compared between cohorts.

Abstract 2022-RA-1306-ESGO Figure 1
Abstract 2022-RA-1306-ESGO Figure 1
View this table:
Abstract 2022-RA-1306-ESGO Table 1

Patient, tumor and treatment characteristics

Results There were 354 (76%) and 114 (24%) women in the pre-Covid and Covid cohorts, respectively. Demographics did not differ between cohorts (table 1). At multidisciplinary team evaluations there were no differences in allocation to primary surgery (PDS), interval surgery (IDS) or chemotherapy only (CT) between cohorts. Surgical complexity scores at PDS and IDS were similar in both cohorts. At PDS significantly more women in the covid cohort had residual disease <10 mm. Type and amount of chemotherapy did not differ between cohorts. Significantly more women in the Covid cohort received PARPi maintenance therapy. A significantly higher cumulative incidence of recurrence was found for the covid cohort (p<0.0003), figure 1a. For women undergoing exploratory laparotomy or IDS the risk of recurrence was higher in the Covid cohort than the pre-Covid cohort during initial 18 months after diagnosis, for IDS HR=2.75 [95% CI, 1.45–5.2], figure 1b.

Conclusion Despite equal surgical capacity and favorable prognostic characteristics, women with advanced stage HGSC diagnosed during the Covid pandemic had a significantly higher risk of recurrence when compared to pre-covid cohort, particularly for women undergoing IDS.

https://doi.org/10.1136/ijgc-2022-ESGO.683

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.